ESMO 2016 | Effect of cabozantinib on quality of life in renal cell carcinoma
Sumanta Pal
Sumanta Kumar Pal, MD of City of Hope , Duarte, CA shares the new research in renal cell carcinoma he is most excited about at the European Society for Molecular Oncology (ESMO) 2016 Congress in Copenhagen, Denmark. He discusses data he is presenting at this congress on quality of life in the context of cabozantinib treatment (NCT01865747). Dr Pal describes the step-wise increase in quality of life seen during the course of therapy with this second-line agent in renal cell carcinoma, and argues why he prefers cabozantinib over other treatment options.
Related videos
2:43 Targeted screening and risk stratification of prostate cancer - updates from the IMPACT study
Rosalind Eeles
2:36 Erdafitinib and hyperphosphatemia in advanced UrC
Scott Tagawa
3:04 Kidney cancer: minimizing toxicities and hassle in adjuvant therapy
Tim Eisen
3:56 TROPHY-U-01: Initial findings
Scott Tagawa
2:34 Updates on JAVELIN renal 101: primary treatment for patients
Laurence Albiges
